Get the Stockscreener App
26.50
1.34%
-0.44
Rapport Therapeutics Inc stock is traded at $26.50, with a volume of 205.62K.
It is down -1.34% in the last 24 hours and down -6.87% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$26.94
Open:
$26.41
24h Volume:
205.62K
Relative Volume:
0.27
Market Cap:
$966.83M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.22%
1M Performance:
-6.87%
6M Performance:
+134.60%
1Y Performance:
+12.53%
1-Day Range:
$25.69
$27.22
1-Week Range:
$25.69
$29.49
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
26.49 | 1.24B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.66 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.42 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.43 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.29 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.45 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
What institutional flow reveals about Rapport Therapeutics Inc.Trade Ideas & Weekly Breakout Opportunity Watchlist - newser.com
Can trapped investors hope for a rebound in Rapport Therapeutics Inc.Portfolio Return Summary & Accurate Entry/Exit Alerts - newser.com
Has Rapport Therapeutics Inc. formed a bullish divergence2025 Short Interest & Real-Time Volume Trigger Notifications - newser.com
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Down 33.3% in October - MarketBeat
Using R and stats models for Rapport Therapeutics Inc. forecastingMarket Performance Summary & Proven Capital Preservation Tips - newser.com
Historical volatility pattern of Rapport Therapeutics Inc. visualizedGold Moves & Real-Time Chart Breakout Alerts - newser.com
Rapport Therapeutics Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
Analyzing Rapport Therapeutics Inc. with risk reward ratio charts2025 Pullback Review & Long Hold Capital Preservation Tips - newser.com
How to recover losses in Rapport Therapeutics Inc. stock2025 Year in Review & Momentum Based Trading Ideas - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pickJuly 2025 News Drivers & Free High Accuracy Swing Entry Alerts - newser.com
What earnings revisions data tells us about Rapport Therapeutics Inc.July 2025 Opening Moves & Free Weekly Watchlist of Top Performers - newser.com
What candlestick patterns are forming on Rapport Therapeutics Inc.Trade Volume Report & Daily Technical Stock Forecast Reports - newser.com
Will Rapport Therapeutics Inc. benefit from macro trendsWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - newser.com
Tools to monitor Rapport Therapeutics Inc. recovery probabilityTrade Exit Summary & Real-Time Market Sentiment Reports - newser.com
Rapport Therapeutics’ RAP-219 Study: A Potential Game-Changer for Bipolar I Disorder - MSN
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 8.1%Still a Buy? - MarketBeat
Is Rapport Therapeutics Inc a good long term investmentEconomic Indicators Overview & Outstanding Return Portfolio - earlytimes.in
Published on: 2025-10-28 05:44:22 - newser.com
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,833 |
150,541 |
579,579 |
| Ceesay Abraham | Chief Executive Officer |
Oct 15 '25 |
Sale |
25.81 |
5,083 |
131,189 |
41,061 |
1.24%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):